tiprankstipranks
SAGE Therapeutics (SAGE)
NASDAQ:SAGE

SAGE Therapeutics Stock Forecast & Price Target

770 Followers
See the Price Targets and Ratings of:

Analyst Rating Consensus

Moderate Buy
9Ratings
4 Buy
5 Hold
0 Sell
Based on 9 analysts giving stock ratings to
SAGE
Therapeutics
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

SAGE Stock Price Prediction

Average Price Target

$56.56
▲(44.43% Upside)
Based on 9 Wall Street analysts offering 12 month price targets for SAGE Therapeutics in the last 3 months. The average price target is $56.56 with a high forecast of $92.00 and a low forecast of $37.00. The average price target represents a 44.43% change from the last price of $39.16.
Highest Price Target$92.00Average Price Target$56.56Lowest Price Target$37.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Upgrade Banner
Mizuho Securities
$37.00
Hold
-5.52%
Downside
Reiterated
SAGE Therapeutics (SAGE) Gets a Hold Rating from Mizuho Securities
Berenberg Bank
$37.00
Hold
-5.52%
Downside
Reiterated
Berenberg Bank Reaffirms Their Hold Rating on SAGE Therapeutics (SAGE)
Goldman Sachs
$73.00
Buy
86.41%
Upside
Reiterated
Goldman Sachs Thinks SAGE Therapeutics' Stock is Going to Recover
Morgan Stanley
$53.00
Hold
35.34%
Upside
Reiterated
Sage Therapeutics (SAGE) PT Lowered to $53 at Morgan StanleyMorgan Stanley analyst Vikram Purohit lowered the price target on Sage Therapeutics (NASDAQ: SAGE) to $53.00 (from $57.00) while maintaining a Equalweight rating.
Piper Sandler
Buy
Reiterated
Sage Therapeutics risk/reward attractive into catalysts, says Piper SandlerSage Therapeutics risk/reward attractive into catalysts, says Piper Sandler
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
VTYXVentyx Biosciences
PRVAPrivia Health Group
RXDXPrometheus Biosciences
IMCRImmunocore Holdings
SKINBeauty Health
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

SAGE Stock Forecast FAQ

What is SAGE’s average 12-month price target, according to analysts?
Based on analyst ratings, SAGE Therapeutics’s 12-month average price target is $56.56.
    What is SAGE’s upside potential, based on the analysts’ average price target?
    SAGE Therapeutics has 44.43% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is SAGE a Buy, Sell or Hold?
          SAGE Therapeutics has a conensus rating of Moderate Buy which is based on 4 buy ratings, 5 hold ratings and 0 sell ratings.
            What is SAGE Therapeutics’s price target?
            The average price target for SAGE Therapeutics is $56.56. This is based on 9 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $92.00 ,the lowest forecast is $37.00. The average price target represents 44.43% Increase from the current price of $39.16.
              What do analysts say about SAGE Therapeutics?
              SAGE Therapeutics’s analyst rating consensus is a ‘Moderate Buy. This is based on the ratings of 9 Wall Streets Analysts.

                What's Included in PREMIUM?
                Make informed decisions based on Top Analysts' activity
                Know what industry insiders are buying
                Get actionable alerts from top Wall Street Analysts
                Find out before anyone else which stock is going to shoot up
                Get powerful stock screeners & detailed portfolio analysis